Cell and Gene Therapy Market Report 2026

Cell and Gene Therapy Market Overview

• Cell and Gene Therapy market size has reached to $21.33 billion in 2025 • Expected to grow to $60.58 billion in 2030 at a compound annual growth rate (CAGR) of 23.3% • Growth Driver: Growing Number Of Clinical Trials Fuels Cell And Gene Therapy Market Growth • Market Trend: Advancing The Cell And Gene Therapy Market With Platform-Agnostic Systems • North America was the largest region in 2025.

What Is Covered Under Cell and Gene Therapy Market?

Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy. The main types of products in cell and gene therapies are cell therapy and gene therapy. Gene therapy is a branch of medicine that focuses on modifying the genetic material of cells to achieve a therapeutic effect or to heal disease by repairing or reconstructing damaged genetic material. The different applications include oncology, dermatology, musculoskeletal, and others and involve various sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and others.

What Is The Cell and Gene Therapy Market Growth Forecast?

The cell and gene therapy market size is expected to see exponential growth in the next few years. It will grow to $60.58 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to development of advanced car-t and genome editing therapies, expansion of clinical trials and research programs, increasing adoption of personalized medicine, rising government support and funding for rare disease treatments, integration of digital platforms for therapy monitoring and patient management. Major trends in the forecast period include increasing adoption of car-t and stem cell therapies, rising investment in gene therapy for oncology and rare diseases, growth in personalized and targeted cell-based treatments, expansion of hospital and ambulatory surgical centers offering advanced therapies, integration of genome editing and viral vector-based technologies in clinical practice.

Global Cell and Gene Therapy Market Segmentation

1) By Product: Cell Therapy, Gene Therapy 2) By Application: Oncology, Neurological Disorders, Other Applications 3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users Subsegments: 1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy 2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

What Is The Driver Of The Cell and Gene Therapy Market?

A growing number of ongoing clinical trials is expected to propel the growth of the cell and gene therapy market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. Clinical trials play a vital role in the development and advancement of cell and gene therapy. They provide a safe and controlled environment to test new therapies and collect data on their safety and efficacy. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, a growing number of ongoing clinical trials is driving the growth of the cell and gene therapy industry.

Key Players In The Global Cell and Gene Therapy Market

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Global Cell and Gene Therapy Market Trends and Insights

Major companies operating in the cell and gene therapy market are increasing their focus on introducing agnostic systems to gain a competitive edge in the market. Agnostic systems refer to systems that are integrated with a variety of different cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub, a new platform-agnostic system that aims to improve connectivity across the cell and gene therapy (CGT) treatment journey to enable an enhanced patient and provider experience. The hub is powered by the company's customer relationship management system and is designed to speed up the benefits investigation process, give a real-time view of therapy development and transportation status, and assist in coordinating patient support.

What Are Latest Mergers And Acquisitions In The Cell and Gene Therapy Market?

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company that develops and sells drugs to improve human health and well-being worldwide, acquired Orchard Therapeutics for an undisclosed amount. With this acquisition, Kyowa Kirin Co. Ltd. aims to enhance its capabilities in developing innovative gene therapies for rare diseases, expanding its therapeutic portfolio, and addressing unmet medical needs. Orchard Therapeutics plc is a UK-based biotech company that specializes in developing innovative cell and gene therapies.

Regional Insights

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cell and Gene Therapy Market?

The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cell and Gene Therapy Market Report 2026?

The cell and gene therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.